Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardio Diagnostics HoldingsCDIO +0.15%49 Cash Ratio is 14.41 as of Mar. 2026, which is 139% above its 10-year median of 6.03. GuruFocus rates CDIO with a GF Score™ of 49/100 and a GF Value™ of $2.77 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,384 Biotechnology companies, Cardio Diagnostics Holdings ranks better than 87.72% on this metric.
Cardio Diagnostics Holdings has a Cash Ratio of 14.41. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cardio Diagnostics Holdings's Cash Ratio or its related term are showing as below:
CDIO'
s Cash Ratio Range Over the Past 10 Years
Min: 0.61 Med: 6.03 Max: 21.53
Current: 14.41
During the past 6 years, Cardio Diagnostics Holdings's highest Cash Ratio was 21.53. The lowest was 0.61. And the median was 6.03.
CDIO's Cash Ratio is ranked better than 87.72% of 1384
companies
in the Biotechnology industry
Industry Median: 2.93
vs CDIO: 14.41
Cardio Diagnostics Holdings (NAS:CDIO) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cardio Diagnostics Holdings Cash Ratio Related Terms
Cardio Diagnostics Holdings Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardio Diagnostics Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings (CDIO) has a Cash Ratio of 14.41 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cardio Diagnostics Holdings and its competitors. This is 139% above median its historical median of 6.03. Over the past decade, Cardio Diagnostics Holdings' Cash Ratio has ranged from 0.61 to 21.53. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #170 out of 1384 companies in the Biotechnology industry, placing it in the top 12.3%.
Is Cardio Diagnostics Holdings' Cash Ratio too high?
Cardio Diagnostics Holdings' current Cash Ratio of 14.41 is 139% above median its 10-year median of 6.03. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 21.53. The Biotechnology industry median Cash Ratio is 2.93. Cardio Diagnostics Holdings' value of 14.41 is 391.8% above this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #170 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Cash Ratio compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #170 out of 1384 companies for Cash Ratio. This places Cardio Diagnostics Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Cardio Diagnostics Holdings' value of 14.41 is 391.8% above this benchmark. Historically, Cardio Diagnostics Holdings' own Cash Ratio has ranged from 0.61 to 21.53 over the past decade. While the company's 10-year median is 6.03 vs. the industry median of 2.93, Cardio Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current Cash Ratio of 14.41 is 391.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current Cash Ratio is 14.41, which is 139% above median its own 10-year median of 6.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.3% below its estimated fair value. The current Cash Ratio is 14.41, which is 139% above median its 10-year median of 6.03 and 391.8% above the Biotechnology industry median of 2.93. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Cash Ratio is 14.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued.
The current stock price of $1.57 is trading 43.3% below its estimated GF Value™ of $2.77.
GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.
Key valuation signals for CDIO:
Cash Ratio: 14.41 (139% above median its 10-year median of 6.03)
GF Value™: $2.77 vs. price of $1.57 (43.3% below fair value)
Industry Position: 391.8% above the Biotechnology median (#170 of 1384)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score
Get the complete analysis for CDIO
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
